ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:



The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 07/2022 of 24 March 2022. The right to share options and performance shares may be achieved in March 2025, provided that ALK achieves the pre-agreed targets for vesting and that the employment relationship with the ALK Group has not been terminated by the company on objective grounds or terminated.



The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated in the attached pdf-file.



ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

Attachment



EN
04/03/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ACARIZAX® approved in Canada for treatment of young children

ACARIZAX® approved in Canada for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65. Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing continuously by double digits. The expanded ACARIZAX®...

March 7, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier ...

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner: Bestyrelsen har tidligere tildelt aktieoptioner og performance-aktier i ALK-Abelló A/S, jf. selskabs­meddelelse nr. 07/2022 af 24. marts 2022. Retten til aktieoptioner og performance-aktier kunne opnås i marts 2025, under forudsætning af, at ALK opnår de forud aftalte mål...

March 4, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B shares and associated sec...

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 07/2022 of 24 March 2022. The right to share options and performance shares may be achieved in March 2025, provided that ALK ac...

March 4, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Den amerikanske lægemiddelmyndighed (FDA) godkender ODACTRA® til behan...

Den amerikanske lægemiddelmyndighed (FDA) godkender ODACTRA® til behandling af husstøvmideallergi hos yngre børn ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at den amerikanske lægemiddelmyndighed (FDA) har godkendt ALK's tablet ODACTRA® til behandling af yngre børn med husstøvmideallergi. ODACTRA® er dermed indikeret til behandling af husstøvmide-induceret allergisk rhinitis med eller uden konjunktivitis hos børn i alderen fem til 11 år, foruden patienter i alderen 12 til 65 år. ODACTRA® er en allergi-immunterapi (AIT)-tablet, der opløses under tungen, og hjælper patienter med at re...

February 27, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

FDA approves ODACTRA® for the treatment of house dust mite allergy in ...

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.   ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reli...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch